nLIGHT (LASR) Q2 2026 Earnings Call Transcript

nLIGHT reported Q2 2026 revenue of $82.6M (+34% Y/Y) with record product revenue of $59.4M (+45% Y/Y) and non-GAAP net income of $9.6M (=$0.15/share), alongside record operating cash flow of $20.7M. Management raised the strategic outlook via the JLWS directed-energy contract ceiling of $607M (initially $44M funded), while Q3 guidance of $63M–$73M excludes $17M of delayed shipments tied to optics/materials sourcing constraints from Chinese suppliers. The company guided non-GAAP gross margin at lower sequential levels (products non-GAAP 42.4%, down vs. 44.6% in Q1), and CFO flagged some execution uncertainty for delivering backlog in Q4 despite strong demand.

Analysis

The near-term setup is a classic split between order demand and ship capacity. The company is effectively bottlenecked on a small set of dual-use optical inputs, which means the headline revenue cut is more a timing hit than a demand problem; that typically compresses the stock for 1-4 weeks, then rebounds only when investors get proof the backlog is converting. The bigger second-order effect is that any defense-name with commercial photonics exposure now has a higher probability of a localization/requalification spend cycle, which can depress gross margin for a few quarters even if end demand is strong.

Strategically, JLWS is the more important signal than the quarter itself, but it will not be monetized by the market until there is visible 2027 schedule conversion. The ceiling value matters less than the fact that the program shifts nLIGHT from prototype credibility to repeatable production; that should improve multiple quality if execution holds, but only after the current supply-chain noise clears. In the meantime, the company’s mix is still too small to justify a straight-line rerating on defense alone, especially with the commercial end of the portfolio doing the heavy lifting today.

Contrarian view: consensus may be too quick to extrapolate the China optics issue into a durable structural headwind. The risk is real, but because the affected parts are common rather than bespoke, mitigation can happen faster than models assume. The falsifier for the bull case is not this quarter’s guide; it is a Q4 miss, another delay into 2027, or evidence that JLWS ramps slower than promised. Until then, the stock looks better as a tactical buy on weakness than as a chase at strength.

Key Decisions for Investors

• Buy LASR on post-print weakness for a 3-6 month trade; thesis is backlog conversion plus JLWS credibility outweighing the Q3 guide cut. Risk/reward is attractive if the stock is down on supply-chain fear rather than demand deterioration; stop if management flags the issue still unresolved at the Q4 update.
• Use a call spread in LASR for 3-9 months rather than outright common if liquidity allows; this captures a rerating when investors start pricing 2027 JLWS revenue, while limiting damage if commercial shipments stay impaired longer than expected.
• Pair trade: long LASR / short IPGP or another industrial-laser proxy over the next 1-3 months. The long leg has a defense-powered secular leg and cash-rich balance sheet; the short leg is more exposed to cyclical industrial demand and China-related optics friction.
• Set a watch item on Q4 backlog conversion and any mention of supply-chain requalification. If management confirms recovery and no additional China-driven delays, add to LASR; if not, de-risk quickly because the market will start treating this as a multi-quarter execution problem.